Saturday, Incyte's Phase 3 frontMIND Trial Of Tafasitamab (Monjuvi/Minjuvi) And Lenalidomide Added To R-CHOP Showed A 25% Reduction In Risk Of Disease Progression Or Death Versus R-CHOP For Previously Untreated Diffuse Large Or High-grade B-cell Lymphoma

Loading news article.

Saturday, Incyte's Phase 3 frontMIND Trial Of Tafasitamab (Monjuvi/Minjuvi) And Lenalidomide Added To R-CHOP Showed A 25% Reduction In Risk Of Disease Progression Or Death Versus R-CHOP For Previously Untreated Diffuse Large Or High-grade B-cell Lymphoma | WAPE

Saturday, Incyte's Phase 3 frontMIND Trial Of Tafasitamab (Monjuvi/Minjuvi) And Lenalidomide Added To R-CHOP Showed A 25% Reduction In Risk Of Disease Progression Or Death Versus R-CHOP For Previously Untreated Diffuse Large Or High-grade B-cell Lymphoma

Article summary

Related companies

Comments —